VENETOCLAX AZACITIDINE COMBINATION THERAPY IN FIRST-LINE TREATMENT OF ACUTE MYELOID LEUKEMIA PATIENTS: A SINGLE CENTER EXPERIENCE
Objective: The response of elderly patients with acute myeloid leukemia (AML) to standard induction therapy is quite poor due to higher frequency of adverse genomic features, increased resistance to treatments, comorbidities and performance status. BCL-2 overexpression is implicated in survival of A...
Guardado en:
Autores principales: | Melda Cömert, Tuba Bulduk, Bilge Uğur, Murat Yıldırım, Selim Sayın, Alparslan Merdin, Ebru Kılıç Güneş, Elifcan Aladağ Karakulak, Meltem Aylı |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8b18364c97ed43b6bd1a68128e0a4314 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber M, et al.
Publicado: (2019) -
A RARE CAUSE OF SIDEROBLASTIC ANEMIA: TRNT1 MUTATION
por: Fatma Tuba YILDIRIM, et al.
Publicado: (2021) -
RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
por: EMINE DURAK, et al.
Publicado: (2021) -
THREE CASES WITH BURKITT LYMPHOMA PRESENTING WITH CHOLESTASIS
por: Fatma Tuba YILDIRIM, et al.
Publicado: (2021) -
A CASE DIAGNOSED WITH FOUR DIFFERENT TUMORS
por: Fatma Tuba YILDIRIM, et al.
Publicado: (2021)